Results 191 to 200 of about 111,189 (247)

Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial. [PDF]

Int J Clin Oncol
Kitahiro Y, Minami H, Yamamoto K, Yakushijin K, Kurata K, Sakai R, Saeki M, Okazoe-Hirakawa Y, Iida K, Murase N, Harima I, Kitamura N, Itohara K, Omura T, Sugimoto T, Takakura H, Kitao A, Takahashi M, Shimoyama M, Okuno M, Yano I.   +20 more
europepmc   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, EarlyView.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source

Revisiting B-cell targeted therapies in rheumatoid arthritis: from paradoxical biology to deep immune reset. [PDF]

Front Immunol
Huang M, Dong F, Liu Q, Lin S.
europepmc   +1 more source

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

British Journal of Haematology, EarlyView.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff, Fabian Görke, Vanja Zeremski, Sophia Wollnitza, Evgenii Shumilov, Georg Lenz, Ellen Obstfelder, Inken Hilgendorf, Vladan Vučinić, Andreas Hochhaus, Ulf Schnetzke   +10 more
wiley   +1 more source

Clinical characteristics, diagnosis, treatment, and prognosis of rituximab-induced serum sickness: a retrospective analysis of 39 reported cases. [PDF]

Front Immunol
Huang Y, Li W, Wang Y, Liu X, Huang Y.
europepmc   +1 more source

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center. [PDF]

Arq Neuropsiquiatr
Simon-Nogueira AB, Holanda AC, Rosalem RA, Santillan TIV, Silva GD, Apostolos-Pereira SL, Adoni T, Callegaro D, Spricigo MG, Oliveira MB.   +9 more
europepmc   +1 more source

Diagnosis and management of neutropenia in adults: Expert guidance

British Journal of Haematology, EarlyView.
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte, Cornelia Zeidler, Julia Skokowa, Sabine Mellor‐Heineke, Audrey Anna Bolyard, David Dale   +5 more
wiley   +1 more source

Weekly Cladribine Followed by Rituximab for the Treatment of Hairy Cell Leukemia. [PDF]

EJHaem
Turner JA, Santos J, Pizzuti V, Paton E, Robinson WA.   +4 more
europepmc   +1 more source